Literature DB >> 25238526

Current options for providing sustained analgesia to laboratory animals.

Patricia L Foley1.   

Abstract

The provision of adequate analgesia after an invasive procedure or for general pain management is an important component of laboratory animal care. Choosing the appropriate analgesic requires careful consideration by the investigators, the veterinary team and the institution's ethical review committee. Sustained-delivery analgesics are superior to analgesics with short durations of action because they do not need to be administered multiple times, reducing handling-induced stress to the animal, and they provide sustained plasma concentrations of the analgesic over the treatment period. The author reviews analgesic formulations that have durations of action longer than 12 h and up to 72 h. These options should be considered when appropriate for particular procedures and animal species.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25238526     DOI: 10.1038/laban.590

Source DB:  PubMed          Journal:  Lab Anim (NY)        ISSN: 0093-7355            Impact factor:   12.625


  5 in total

1.  Clinical Management of Pain in Rodents.

Authors:  Patricia L Foley; Lon V Kendall; Patricia V Turner
Journal:  Comp Med       Date:  2019-12-10       Impact factor: 0.982

2.  Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats.

Authors:  M Guarnieri; C Brayton; R Sarabia-Estrada; B Tyler; P McKnight; L DeTolla
Journal:  J Vet Med       Date:  2017-04-09

3.  Bone morphogenetic protein and activin membrane-bound inhibitor overexpression inhibits gastric tumor cell invasion via the transforming growth factor-β/epithelial-mesenchymal transition signaling pathway.

Authors:  Chun-Ling Yuan; Rong Liang; Zhi-Hui Liu; Yong-Qiang Li; Xiao-Ling Luo; Jia-Zhou Ye; Yan Lin
Journal:  Exp Ther Med       Date:  2018-04-20       Impact factor: 2.447

4.  Association of nausea with buprenorphine analgesia for rats.

Authors:  R Sarabia-Estrada; A Cowan; B M Tyler; M Guarnieri
Journal:  Lab Anim (NY)       Date:  2017-05-22       Impact factor: 12.625

5.  Lack of adverse effects during a target animal safety trial of extended-release buprenorphine in Fischer 344 rats.

Authors:  Alan Cowan; Rachel Sarabia-Estrada; Gina Wilkerson; Patrick McKnight; Michael Guarnieri
Journal:  Lab Anim (NY)       Date:  2016-01       Impact factor: 12.625

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.